Davis Polk to Launch EU Antitrust Practice in Brussels
Davis Polk today announced that the firm is launching a European antitrust practice in Brussels. The practice will be led by Jürgen Schindler and Frances Dethmers.
“The European Commission is a critical antitrust authority. We are excited to be able to offer our clients sophisticated antitrust capabilities with respect to matters under EU law,” said Neil Barr, Davis Polk’s Managing Partner. “We are thrilled to welcome Jürgen and Frances to Davis Polk.”
The firm’s office in Brussels will open in 2023.
Mr. Schindler and Ms. Dethmers join the firm from Allen & Overy, where both served as partners and Mr. Schindler as co-head of the global competition and antitrust group. Mr. Schindler has extensive experience advising clients on complex international, EU and German merger control, cartel and abuse of dominance cases. His practice encompasses a broad range of sectors, including energy, finance, technology, transport (shipping and airlines), raw materials, chemicals, pharmaceuticals, and consumer and industrial products. In addition, Mr. Schindler litigates before the European courts in Luxembourg.
Mr. Schindler’s practice has extensive geographic coverage; he has advised clients in Europe, the United States, Latin America, Asia and the Middle East. He is admitted to practice in Germany, Belgium and New York. He will join Davis Polk as a partner.
He is a Non-Governmental Adviser to the European Commission and to the German Competition Authority at the International Competition Network (ICN), which includes around 140 competition authorities worldwide, and he regularly contributes to the ICN’s cartel and merger working groups. In addition, he is a long-time editorial board member of the ABA’s Antitrust Magazine Online.
Ms. Dethmers’ practice focuses on international, EU and Dutch competition law. She is an economist and a qualified lawyer. She has extensive experience advising clients from a wide range of industries (in particular, pharmaceuticals, health and life sciences, consumer and industrial products, chemicals and packaging) on highly complex merger control procedures, as well as on cartel investigations, abuse of dominance investigations, intellectual property issues and licensing and distribution agreements. Prior to working in private practice, she worked at the Dutch Competition Authority and the European Commission. Her background as an economist gives her unique insight into the economic concepts and analytical tools at the heart of competition law. She is admitted to practice in the Netherlands. She will join Davis Polk as Special Adviser – EU Antitrust.
“Jürgen and Frances are exceptional lawyers with an outstanding reputation in Brussels, and we are thrilled to have them on board to help us launch our EU antitrust practice,” said Art Burke, head of Davis Polk’s Antitrust & Competition practice. “Their significant experience across merger control matters, cartels and antitrust litigation will benefit our clients greatly and will further solidify our position as a leading global antitrust firm.”
Davis Polk is recognized as a preeminent firm in antitrust and competition law, including with top-tier rankings from publications such as Global Competition Review, Benchmark Litigation and Chambers USA. Clients rely on Davis Polk’s deep experience across the full spectrum of antitrust and competition matters. The firm steers clients through sensitive antitrust investigations and high-stakes litigation, including class actions and government enforcement actions. Davis Polk also serves in a lead role for large defense groups, including in cases alleging cartel behavior in numerous industries and financial markets. Having addressed and resolved antitrust issues presented by thousands of transactions across all economic sectors, the firm is widely recognized in particular for its work on cross-border combinations and routinely acts as coordinating counsel for international merger control review for complex transactions.
Mr. Schindler said, “Frances and I are very excited to be joining Davis Polk, a firm we have long held in high esteem. We have been struck by the strong culture that permeates throughout the firm, and we very much look forward to working with this fantastic team and helping the firm to execute on this strategic expansion of its global antitrust capabilities. We are very grateful for our time as partners at Allen & Overy.”
Ranked as a leading EU competition lawyer by Chambers Europe, Mr. Schindler in 1999 graduated from the University of Hamburg and earned an LLM in European Law from the College of Europe in Bruges. In 2007, he earned an LLM from Georgetown University Law Center focusing on U.S. antitrust law and economics. Ms. Dethmers earned a master’s degree in economics in 1998 and a master’s degree in law in 2001, both from the University of Amsterdam.
About Davis Polk.
Davis Polk & Wardwell LLP (including its associated entities) is an elite global law firm with world-class practices across the board. Clients know they can rely on us for their most challenging legal and business matters. From offices in the world’s key financial centers and political capitals, our more than 1,000 lawyers collaborate seamlessly to deliver exceptional service, sophisticated advice and creative, practical solutions. Visit davispolk.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Director of PR & Communications
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dentalis Animal Health appoints Advisory Board4.2.2023 15:09:00 CET | Press release
Dentalis Animal Health, a company specializing in Oral Health care for companion animals, has announced the appointment of its Advisory Board. Michael Kelly Michael Kelly is an Animal Health Pharmaceutical Industry veteran with broad international business experience. A graduate of Harvard Business School and Cornell University, Michael was hired by Ciba-Geigy to begin his post graduate career in Switzerland. Eventually ending up in the Novartis Animal Health US Division (following the Ciba-Sandoz merger) he rose to CFO and VP of North America. In 2009 Kelly joined Piedmont Animal Health (PAH), a drug development company, and served various roles including CFO, COO and President. During his tenure at PAH the organization received more FDA Companion Animal Drug approvals than any other Company in the Industry. Dr Stephanie Livermore Dr. Stephanie Livermore has been practicing companion animal medicine and surgery since her graduation from the University of Guelph in 2008. Dr. Livermore
Autel Brings MaxiCharger DC Compact to eCarExpo and Signs Partnership Agreement with Leading Charging Operator Eways4.2.2023 09:00:00 CET | Press release
Autel, a leading provider of automotive electronics and diagnostic equipment and tools, exhibited for the first time at eCarExpo, the largest electric vehicles fair in the Nordic countries, on February 3-5, 2023, in Friends Arena, Stockholm. Autel brought its portfolio of products featuring the recently launched electric vehicle charger the MaxiCharger DC Compact. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230204005001/en/ Autel signs partnership agreement with leading charging operator Eways (Photo: Business Wire) As Autel's newly launched DC charger for EVs, the MaxiCharger DC Compact is not only sleek and compact with a 21.5-inch LCD touchscreen, but also powerful enough to provide up to 47kW of power for the European version. Either placed on a pedestal, or set on wheels for ultimate portability, the MaxiCharger DC Compact is perfect for charging operators wanting to provide their customers with a quick charge option
U.S. FDA Approves Takeda’s TAKHZYRO ® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older4.2.2023 00:48:00 CET | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the expanded use of TAKHZYRO® (lanadelumab-flyo) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in pediatric patients 2 to <12 years of age.1 Prior to today’s approval, the only approved routine prophylaxis treatment options for children 6 to <12 years of age required dosing every three to four days,and children with HAE 2 to <6 years of age had no approved prophylaxis treatment, making TAKHZYRO the first prophylaxis treatment for this age group.1-5 The recommended dose is 150 mg/1 mL solution in a single-dose prefilled syringe every four weeks in patients 2 to <6 years of age and every two weeks in patients 6 to <12 years of age.1 HAE attacks can involve serious and debilitating swelling in the abdomen, face, feet, genitals, hands and throat.5,7 Potentially fatal upper airway angioedema has been reported i
SLB Completes Acquisition of Gyrodata Incorporated3.2.2023 22:05:00 CET | Press release
SLB (NYSE: SLB) today announced it has completed the acquisition of Gyrodata Incorporated, a global company specializing in gyroscopic wellbore positioning and survey technology. The transaction will incorporate Gyrodata’s wellbore placement and surveying technologies within SLB’s Well Construction business, bringing customers innovative drilling solutions. This combination will improve wellbore quality and reduce drilling risk to unlock even the most remote and complex reservoirs. Integrating three-axis solid state gyro measurements with the latest SLB technological innovations will help ensure tighter trajectory control, reduce data acquisition time and improve the decision-making process—resulting in greater overall drilling efficiency. “I’m excited for this historic moment that will bring innovative solutions to the SLB Well Construction division and our industry,” said Jesus Lamas, president, Well Construction, SLB. “The technology-driven acquisition of Gyrodata is aligned with SL
Gallagher Re Joins ABIR and EY as 2023 Bermuda Risk Summit Headline Sponsors3.2.2023 16:17:00 CET | Press release
The Bermuda Business Development Agency (BDA) is pleased to announce that Gallagher Re has joined the Association of Bermuda Insurers and Reinsurers (ABIR) and EY as headline sponsors of the second annual Bermuda Risk Summit. Adam Schwebach, Executive Vice President, Gallagher Re, said, “Gallagher Re is proud to support the second Bermuda Risk Summit, an annual event that showcases the breadth and versatility of Bermuda’s globally significant risk market. This event serves as a timely opportunity to connect with industry leaders ahead of midyear renewals and we applaud the BDA for their efforts in making the Bermuda Risk Summit a success.” David Hart, BDA CEO, said, “We are just so excited to welcome Gallagher Re as our third and final headline sponsor, along with ABIR and EY. The theme of the 2023 Bermuda Risk Summit, being held from March 6-8, 2023, at the Hamilton Princess & Beach Club is ‘Innovation, Sustainability and Collaboration. We anticipate an even stronger attendance level